Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Ferrante

Showing results (41-50 of 350) with videos related to

Pageof 35
Sort By:
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 24, 2019
Long-term outcome of immunomodulator use in pediatric patients with inflammatory bowel diseaseKaren van Hoeve, Ilse Hoffman, André D'Hoore, et al.
Expert Opinion on Biological Therapy|November 12, 2013
Targeting TNF-α for the treatment of inflammatory bowel diseaseThomas Billiet, Paul Rutgeerts, Marc Ferrante, et al.
Expert Opinion on Drug Safety|June 3, 2017
A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseasesBram Verstockt, Barbara Deleenheer, Gert Van Assche, et al.
Journal of Crohn'S & Colitis|September 4, 2016
Sarcoidosis-Like Lesions: Another Paradoxical Reaction to Anti-TNF Therapy?Amelie Decock, Gert Van Assche, Séverine Vermeire, et al.
Inflammatory Bowel Diseases|January 9, 2007
Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictorsTibor Hlavaty, Marc Ferrante, Liesbet Henckaerts, et al.
Gut|September 28, 2022
Holistic healthcare in inflammatory bowel disease: time for patient-centric approaches?Padhmanand Sudhakar, Judith Wellens, Bram Verstockt, et al.
Inflammatory Bowel Diseases|November 9, 2021
Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBDAnnick Moens, Bram Verstockt, Dahham Alsoud, et al.
The Lancet. Gastroenterology & Hepatology|June 3, 2023
Tofacitinib concentrations in plasma and breastmilk of a lactating woman with ulcerative colitisMette Julsgaard, Uma Mahadevan, Thea Vestergaard, et al.
The American Journal of Gastroenterology|September 27, 2023
Utility of the Serum-Based Endoscopic Healing Index in Monitoring Therapeutic Response in Ulcerative ColitisDahham Alsoud, Jessica Ho, João Sabino, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 14, 2023
Therapeutic Drug Monitoring Can Guide the Intravenous-to-Subcutaneous Switch of Infliximab and Vedolizumab: A Simulation StudyZhigang Wang, Bram Verstockt, João Sabino, et al.
Pageof 35

Showing results (41-50 of 350) with videos related to

Sort By:
Pageof 35
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 24, 2019
Long-term outcome of immunomodulator use in pediatric patients with inflammatory bowel diseaseKaren van Hoeve, Ilse Hoffman, André D'Hoore, et al.
Expert Opinion on Biological Therapy|November 12, 2013
Targeting TNF-α for the treatment of inflammatory bowel diseaseThomas Billiet, Paul Rutgeerts, Marc Ferrante, et al.
Expert Opinion on Drug Safety|June 3, 2017
A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseasesBram Verstockt, Barbara Deleenheer, Gert Van Assche, et al.
Journal of Crohn'S & Colitis|September 4, 2016
Sarcoidosis-Like Lesions: Another Paradoxical Reaction to Anti-TNF Therapy?Amelie Decock, Gert Van Assche, Séverine Vermeire, et al.
Inflammatory Bowel Diseases|January 9, 2007
Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictorsTibor Hlavaty, Marc Ferrante, Liesbet Henckaerts, et al.
Gut|September 28, 2022
Holistic healthcare in inflammatory bowel disease: time for patient-centric approaches?Padhmanand Sudhakar, Judith Wellens, Bram Verstockt, et al.
Inflammatory Bowel Diseases|November 9, 2021
Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBDAnnick Moens, Bram Verstockt, Dahham Alsoud, et al.
The Lancet. Gastroenterology & Hepatology|June 3, 2023
Tofacitinib concentrations in plasma and breastmilk of a lactating woman with ulcerative colitisMette Julsgaard, Uma Mahadevan, Thea Vestergaard, et al.
The American Journal of Gastroenterology|September 27, 2023
Utility of the Serum-Based Endoscopic Healing Index in Monitoring Therapeutic Response in Ulcerative ColitisDahham Alsoud, Jessica Ho, João Sabino, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 14, 2023
Therapeutic Drug Monitoring Can Guide the Intravenous-to-Subcutaneous Switch of Infliximab and Vedolizumab: A Simulation StudyZhigang Wang, Bram Verstockt, João Sabino, et al.
Pageof 35